口服抗凝药的过去、现在与未来  

The past,present and future of oral anticoagulants

作　　者：胡志成[1] 姚焰[1] HU Zhi-cheng;YAO Yan(Department of Cardiology,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)

机构地区：[1]中国医学科学院北京协和医学院国家心血管病中心阜外医院心内科,北京市100037

出　　处：《中国心血管病研究》2020年第7期582-585,共4页Chinese Journal of Cardiovascular Research

基　　金：国家自然科学基金(81970285,81600275)。

摘　　要：口服抗凝药(OAC)对于预防以及治疗血栓栓塞性疾病该病具有重要的临床价值.作为维生素K拮抗剂,华法林曾长期作为OAC的唯一选择.近年来,非维生素K拮抗剂口服抗凝药(NOAC)因相对简单的药物间相互作用以及无需检测凝血功能等特点极大的提高了患者服药便利性,迅速在临床上得到广泛应用.但该类药物仍存在长期应用出血风险偏高、消化道出血风险较华法林增加等问题.目前以FⅪ为靶点的下一代口服抗凝药正在积极研发中,有望在未来为血栓栓塞性疾病患者提供更为优异的药物选择.Oral anticoagulants(OAC)are crucial to the treatment of thrombocmbolic discases.As vitamin K antagonist,warfarin once was the mainstay of OAC therapy.In recent years,non-vitamin K antagonist oral anticoagulants(NOAC)are widely used in clinical practice for their simple drugs interaction and convenience for free of coagulation monitoring.However,NOAC remain hemorrhage threat for patients with long-term anticoagulation therapy indication and increase the chance of gastrointestinal bleeding.Since that,next generation OAC targeting factor Ⅺ are under research and expected to provide the potential for better anticoagulation therapy.

关 键 词：血栓栓塞性疾病 口服抗凝药 发展 

分 类 号：R54[医药卫生—心血管疾病]